Companies › NGGT (Suzhou) Biotechnology
2 active drug programs in 2 registered trials: 2 Phase 1; Ophthalmology, Metabolic and endocrine; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NGGT002 adeno-associated viral vector with human phenylalanine hydroxylase gene | PAH | Phase 1 | Phenylketonurias | Aug 2027 |
| NGGT001 AAV-mediated CYP4V2 gene delivery via subretinal injection | CYP4V2 | Phase 1 | Bietti Crystalline Corneoretinal Dystrophy | Sep 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06687733 | NGGT002 | Phase 1 | Phenylketonurias | Metabolic and endocrine | Aug 2027 |
| NCT06706427 | NGGT001 | Phase 1 | Bietti Crystalline Corneoretinal Dystrophy | Ophthalmology | Sep 2029 |
BioMarin Pharmaceutical Shanghai Vitalgen BioPharma PTC Therapeutics Chongqing Peg-Bio Biopharm NGGT Agios Pharmaceuticals
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.